.Attribute Medication, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for introduction of people with MASLD and size of liver results in cardio– kidney– metabolic trials, when data recommend mechanistically tenable advantages and scientific protection– as well as lays out points to consider for trial style and also regulative commendation.